Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All regdanvimab studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchRegdanvimabRegdanvimab (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Effectiveness of regdanvimab on clinical outcomes in COVID-19 infected patients on hemodialysis

Lee et al., Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfae069.1573
May 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 59% unadjusted Improvement Relative Risk Regdanvimab for COVID-19  Lee et al.  EARLY TREATMENT Is early treatment with regdanvimab beneficial for COVID-19? Retrospective 230 patients in South Korea (December 2020 - November 2021) Lower mortality with regdanvimab (p=0.0022) c19early.org Lee et al., Nephrology Dialysis Transp.., May 2024 Favorsregdanvimab Favorscontrol 0 0.5 1 1.5 2+
35th treatment shown to reduce risk in March 2022
 
*, now with p < 0.00000000001 from 11 studies, recognized in 27 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 81 treatments. c19early.org
Retrospective 230 hemodialysis patients with COVID-19, showing lower mortality with regdanvimab. Details of the adjusted results are not provided.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2, BA.4, BA.51, ХВВ.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.12.
This study is excluded in the after exclusion results of meta analysis: minimal details provided.
risk of death, 59.4% lower, RR 0.41, p = 0.002, treatment 10 of 77 (13.0%), control 49 of 153 (32.0%), NNT 5.3, unadjusted.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lee et al., 23 May 2024, retrospective, South Korea, peer-reviewed, 6 authors, study period 1 December, 2020 - 30 November, 2021.
This PaperRegdanvimabAll
Abstract: Abstracts | i2507 Abstract citation ID: gfae069.1573 #616 Effectiveness of regdanvimab on clinical outcomes in COVID-19 infected patients on hemodialysis Young-Ki Lee1 , Youn Kyung Kee2 , Hayne Cho Park1 , Ajin Cho1 , Do Hyoung Kim1 and Jong-Woo Yoon3 1 Hallym University College of Medicine, Kangnam Sacred Heart Hospital, Seoul, Republic of South Korea Hallym University College of Medicine, Kangdong Sacred Heart Hospital, Seoul, Republic of South Korea 3 Hallym University College of Medicine, Chuncheon Sacred Heart Hospital, Republic of South Korea 2 Method: We conducted a retrospective study of 230 HD patients hospitalized with COVID-19 infection between December 1, 2020 and November 30, 2021. Of these, 77 (33.5%) were treated with regdanvimab alone or in combination with dexamethasone or remdesivir during hospitalization (regdanvimab group), and 153 (66.5%) did not treat with regdanvimab (non-regdanvimab group). We compared in-hospital mortality rate according to the use of regdanvimab and investigated the factors associated with mortality. Results: The mean age of the patients was 67.9 ± 12.1 years, with 214 (93%) patients aged 50 years or older. There were no significant differences in demographics and comorbidity between the regdanvimab and non-regdanvimab groups. Fifty-nine deaths occurred during hospitalization, 49 (32%) in the non-regdanvimab group and 10 (13%) in the regdanvimab group, and mortality rate was significantly higher in the non-regdanvimab group than that in the regdanvimab group (P=0.001, Fig.). Multivariate Cox regression analysis showed that malignancy (P=0.001), low oxygen saturation<95% at admission (P=0.003), and administration of antibiotics and regdanvimab (P=0.007 and P=0.002, respectively) were significantly associated factors with mortality. Conclusion: Regdanvimab administration is beneficial in improving prognosis in hospitalized COVID-19 patients on HD. Considering the vulnerability of ESKD patients to infection, regdanvimab may be considered as a therapeutic option in COVID-19 patients on HD. Figure: Background and Aims: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (COVID-19), there are lack of effective and proven treatments for the COVID-19 patients with end-stage kidney disease (ESKD). The present study aims to evaluate the effectiveness of regdanvimab on clinical outcomes in COVID-19-infected patients on hemodialysis (HD).
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit